Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx (COVID-19)
Virus Infection, RNA, Effect of Drug, Efficacy, Self
About this trial
This is an interventional prevention trial for Virus Infection, RNA focused on measuring Viral load, PVP-I, SARS-CoV-2, Shelf-life, Stability
Eligibility Criteria
A. Moderately ill COVID-19 patient and asymptomatic to mild COVID-19 patent having multiple comorbidity
Inclusion Criteria
- Hospital admitted patients tested positive COVID-19 within 24 hours in the laboratory by RT-PCR.
- Patients with asymptomatic, mild to moderate illness of COVID-19.
- Age group 18 year and above.
- Consent of the patients, wish to be included in the study willingly.
Exclusion Criteria:
- Patients with critical COVID-19 and moderate COVID-19 with other complication.
- Patients having thyroid dysfunction, pregnant or lactating mother.
- It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma.
- Patients allergic to iodine should be avoided
- Have participated in other clinical study
- Subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.
B. Healthy Individual
Inclusion Criteria:
- Healthy individual (non COVID-19)
- Age -18 years and above (as below18 years lesser concentration of drug may be required).
- Consent of the participants who wish to participate.
Exclusion criteria:
- Participants who has any major comorbidity.
- Participants having thyroid dysfunction, pregnant or lactating mother.
- It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma.
- Participants allergic to iodine should be avoided
- Have participated in other clinical study
- Subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.
Sites / Locations
- Bangladesh Reference Institute for Chemical Measurements
- Dhaka Medical College Hospital
- Kurmitola General Hospital
- Kuwait-Moitree Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Oral and nasal spray to moderately ill COVID-19 positive patient
Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
Oral and nasal spray to healthy volunteer
Oral and nasal spray by distilled water to control group
Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: Single
Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: hourly for 4 hours in a single day
Drug Name: Povidone-Iodine Dosage form: 0.6% Povidone-Iodine Dosage: 2 puff 0.6% PVP-I in each nostril and 2 puff inside mouth Frequency and duration: 3-4 times interval but not more than 4 times a day for 30 days
Placebo comparator: Distilled water Dosage form: Oral and Nasal spray will be provided by Distilled water